Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

Researchers assessed the global burden of breast cancer in boys and men aged 15-64 years between 1990 and 2021.

The Trump administration’s immigration policies are having negative effects on health care, impacting patients and health care workers alike.

This analysis indicates that proposed Medicaid reforms would have far-reaching consequences beyond federal budget savings, including negative health outcomes, economic losses, and health care system ...

The FDA has approved once-monthly dosing of Elrexfio (elranatamab-bcmm) for certain patients with relapsed or refractory multiple myeloma.

The US Food and Drug Administration (FDA) has granted priority review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle invasive bladder ...

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Chemotherapy can increase mutation burden and change the cell population structure of normal blood, which contributes to long-term adverse effects such as second malignancies and infertility, ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Thousands of workers at federal health agencies lost their jobs this week after a US Supreme Court ruling cleared the way for the Trump administration to move forward with major staffing cuts.

Breastfeeding did not appear to be associated with a higher risk of developing locoregional recurrences or contralateral breast cancers,” researchers wrote.